Suzhou Ribo Bioscience Becomes Jiangsu's First New Listing of the Year with Hong Kong IPO

Source: MicroNews Jiangsu

At 9:30 this morning, the resounding sound of gongs heralded Kunshan's "good start" to the New Year.

Suzhou Ribo Life Science Co., Ltd. Successfully Listed on the Main Board of the Hong Kong Stock Exchange, BecomingThe First Listed Company in Jiangsu This Year。

So far, Kunshan has accumulated 51 listed companies both domestically and overseas, continuing to stand at the forefront of similar cities in China as a leader.

In this IPO, Ribo Life Science issued a total of 31.6104 million shares at HKD 57.97 per share, raising over HKD 1.8 billion. This influx of capital will be used to accelerate the clinical development and commercialization of its innovative therapies, providing new treatment options for patients worldwide.

Ribo Life Science is headquartered in Kunshan, with research and development centers established in Beijing and Gothenburg, Sweden. Currently, the company owns a self-controlled, fully integrated small nucleic acid drug research and development platform that supports studies at all stages from early research to industrialization. Its products cover four major chronic disease areas: cardiovascular, metabolic, liver, and kidney. Seven of the company's self-developed drugs have entered the clinical trial stage, four of which are in Phase II clinical trials.

Its core product, RBD4059, is the world's first clinical-stage small nucleic acid drug for the treatment of thrombotic diseases. Compared with traditional treatments, this drug has significant advantages of ultra-long efficacy and low risk of bleeding, offering a more convenient and safer option for patients requiring long-term medication.

Standing at the starting year of the "15th Five-Year Plan," Kunshan, with its deep industrial foundation and open and inclusive development environment, is seizing the opportunities of capital market reform. Using China's first financial reform pilot zone with cross-strait characteristics as a platform, Kunshan continues to guide enterprises in leveraging the capital market to strengthen, optimize, and expand through building a full-chain listing service system, enhancing the cultivation of listed reserve teams, and deepening cooperation with domestic and overseas stock exchanges.

Among them, Zelgen Biopharma became the first biopharmaceutical stock on the STAR Market.Harsen Co., Ltd.Becoming the first Taiwan-invested enterprise in Jiangsu to be listed on the Shanghai Stock Exchange Main Board,Longteng OptoelectronicsBecoming the first state-owned holding company listed on the STAR Market in Jiangsu, with a cumulative total of 51 listed companies both domestically and overseas, including 35 listed in China and 16 listed overseas, and the number of companies listed on the New Third Board exceeding 100.